Short‐Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open‐Label, Randomised Controlled Trial
Authors' conclusion
In overweight/obese women with PCOS, low-dose tirzepatide combined with MET was associated with greater reductions in body weight and visceral fat, along with improvements in metabolic and reproductive outcomes compared with MET monotherapy.
Study context
- Population
- Overweight/obese Chinese women with polycystic ovary syndrome (PCOS)
- Participants
- 60 women
- Comparison
- Low-dose tirzepatide + metformin vs metformin monotherapy
- Primary endpoint
- Change in body weight
- Follow-up
- 16 weeks
Methodological detailsprospective, open-label, After week 16, all switched to metformin (MET) monotherapy; barrier contraception for 8 weeks; pregnancy outcomes evaluated weeks 25–48
- Prospective
- Open-label
- After week 16, all switched to MET monotherapy; barrier contraception for 8 weeks; pregnancy outcomes evaluated weeks 25–48
Primary result
As reported in the abstract
Combined with metformin (COM)
−10.4
± 3.5 · kg
MET
−1.7
± 2.5 · kg
P < 0.001
Secondary outcomes
| Outcome | COM | MET | P value |
|---|---|---|---|
| Change in BMI · 16 weeks | −4.12 ± 1.37 kg/m² | −0.68 ± 1.82 kg/m² | P < 0.001 |
| Change in visceral adipose tissue (VAT) · 16 weeks | −34.13 ± 15.33 cm² | −4.67 ± 9.59 cm² | P < 0.001 |
- Menstrual cycle recovery · higher with COM
- P = 0.013
- Total pregnancy rate · weeks 25 to 48 · higher with COM
- P = 0.014
Reproductive endocrine-metabolic parameters · 16 weeks
- Greater reductions in reproductive endocrine-metabolic parameters with COM vs MET
Original publication
Short‐Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open‐Label, Randomised Controlled Trial. Diabetes Obes Metab. Published 3 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →